Skip to main content

Tweets

In Dec 2025, the FDA qualified total hip bone mineral density (BMD) assessed by DXA as a validated surrogate endpoint for osteoporosis clinical trials. Previously OP trials required fracture endpoints as primary efficacy measures, necessitating large 2-5 yr studies https://t.co/5t9rftwX4A
Dr. John Cush @RheumNow ( View Tweet )
1 hour ago
A 2 yr. old female pt reported w/ a a novel P435S gain-of-function variant in TLR7 (thought pathogenic in SLE) - pt dx w/ juvenile SLE, recurrent infection, and neuroinflammatory features. A review of 12 other TLR7 GOF variants revealed similar SLE associations. https://t.co/NU553QwCtj
Dr. John Cush @RheumNow ( View Tweet )
3 hours ago
"I need the courage to start, the wisdom to say good and the religion to make it a habit" - Ronan Kavanagh of Galway

Dr. John Cush @RheumNow ( View Tweet )

6 hours 59 minutes ago
ADJUST trial (248 JIA pts w/ Uveitis & inactive >6mos, either continued or weaned off adalimumab. ADA weaning resulted in more flares (68% vs 14%, mostly uveitis) w/ no protection from background DMARD Rx. Restarting ADA was mostly effective. https://t.co/ZWHfPl2UNl https://t.co/Fk1HES2UIc
Dr. John Cush @RheumNow ( View Tweet )
9 hours ago
2025 Lancet review https://t.co/Qbwup6QxZK of Osteoarthritis did not mention/endorse Rx w/ platelet rich plasma (PRP) prompting several letters of protest. Read the authors response: Despite the popularity of PRP, there are few PBO controlled high quality studies to prove its https://t.co/RCaQVXvvfK
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
FIBROSCANS in 60 RA pts on #MTX for 5 yrs w/ liver studies. Mean age = 39.5yrs, w/ Dz Dur 8.2 yrs, mean BMI 24.4 & MTX 12.5–25 mg for ~8 yrs (cum dose 6728mg). All had normal AST, ALT, APRI, Abd US; fibroscan score = 170 ((steatosis grade 0). Only 4(6.7 %) had mild, fibrosis https://t.co/7SACsEYi37
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
New for RheumNow Live 2026! Get more from RheumNow Live 2026—before the meeting begins. Introducing Dr. Mike Putman, Pre-Learn Director, bringing you speaker-selected Pre-Learns and concise video summaries released weekly for registered attendees. 🎥 Watch Now: This week’s PsA https://t.co/vv5XP7EMfu
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
A JAKi in GCA: 2-year efficacy and safety results in a Phase 3 study Discover how continued treatment with a JAKi impacted disease remission and steroid use. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/Tm8m43ZXBM https://t.co/3jHrTCmI6x
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Nursing Shortage Could Worsen Due to Limited Student Loans On 11/6, a DOE rule-making committee released a new proposed framework excluding nursing from the so-called "professional degree" category -- a plan which, if finalized, would limit nurses' access to certain student https://t.co/0zpznqgdb7
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
GC dose and tapering may influence serious infection risk in patients with GCA. Discover the key safety outcomes observed during a year of JAKi therapy in a Phase 3 trial. Sponsored by AbbVie Medical Affairs +Health Impact. https://t.co/1B5dj7KJJr https://t.co/aRMAdanFhb
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Rheumatoid & Inflammation Testing https://t.co/tEkJWGp7DK https://t.co/ZO4BV2mmhn
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
QD Clinic: Sjogren's Beyond the Dryness Caitlin Hill, FNP, and David Maniscalco, MD, Santa Rosa, CA present this QD Clinic: Sjogren's - Beyond the Dryness. https://t.co/4VHRmBm7GC https://t.co/pQV8klTzZV
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
×